TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma

To join this study, people need to be at least 18 years old and have a specific type of stomach or food pipe cancer that doctors believe can be removed with surgery. Your doctors will need to check your general health, including your blood counts, liver, and kidney function, to make sure you are well enough for the treatments involved. They will also look at a specific marker on your cancer called PD-L1; you can still join regardless of what your PD-L1 status is.

You should also be able to visit the hospital for treatments and check-ups during the study period. If you are a woman who could become pregnant, you would need to agree to use effective contraception during and for a period after the study treatment. Basically, the medical team will make sure you meet several health requirements to ensure it's safe for you to take part.

If you decide to take part, you'll first have some tests to confirm you're suitable. The treatment plan involves several stages. You will receive chemotherapy alongside durvalumab for up to four months (eight 2-week chemotherapy cycles and four 4-week durvalumab cycles). After this initial treatment, you'll have surgery to remove the cancer, typically 1 to 2 months later. Following your surgery, you will then receive durvalumab alone for up to 10 more cycles, which means you could be on this part of the treatment for up to 10 months. You will have regular appointments and tests throughout this period and during follow-up to monitor your health and the treatment's effects. The total duration of active treatment and follow-up will depend on your individual response and how many durvalumab cycles you receive after surgery.